Amgen Gets US Infliximab Nod

Amgen’s Avsola Rival To Remicade Is Its Fourth FDA-Approved Biosimilar

 
• By Dave Wallace

Amgen has received its fourth US biosimilar approval for its Avsola infliximab rival to Janssen’s Remicade.

Amgen
Amgen has received an FDA approval for its Avsola version of infliximab • Source: Shutterstock

More from Biosimilars

More from Products